The role of endothelial function and its assessment in rheumatoid arthritis

Faisel Khan, Bernat Galarraga, Jill J. F. Belch

    Research output: Contribution to journalReview article

    61 Citations (Scopus)

    Abstract

    Patients with rheumatoid arthritis (RA) have a reduced life expectancy when compared with the general population, largely attributable to cardiovascular disease. Factors that contribute to this increased cardiovascular risk include traditional risk factors, which account for only part of the excess, along with manifestations of the disease itself. RA is characterized by inflammation, which also is a key component in the development of atherosclerosis. Inflammation leads to the activation of endothelial cells, which, through an increase in the expression of leukocyte adhesion molecules, promotes a pro-atherosclerotic environment. Endothelial dysfunction is an early preclinical marker of atherosclerosis, and is commonly found in patients with RA. Several methods are available for the assessment of endothelial function, such as flow-mediated dilatation and laser Doppler flowmetry combined with iontophoresis, each with its own advantages and limitations. Studies have shown that endothelial dysfunction in RA is closely associated with inflammation, and therapeutic reduction of inflammation leads to improvements in endothelial function. As such, assessments of endothelial function could prove to be useful tools in the identification and monitoring of cardiovascular risk in patients with RA. Given the increase in cardiovascular mortality associated with RA, effective management must involve prevention of cardiovascular risk, in addition to control of disease activity and inflammation.

    Original languageEnglish
    Pages (from-to)253-261
    Number of pages9
    JournalNature Reviews Rheumatology
    Volume6
    Issue number5
    DOIs
    Publication statusPublished - May 2010

    Keywords

    • C-REACTIVE PROTEIN
    • CARDIOVASCULAR RISK-FACTORS
    • IMPAIRED MICROVASCULAR FUNCTION
    • FLOW-MEDIATED DILATATION
    • POPULATION-BASED COHORT
    • CORONARY-HEART-DISEASE
    • FACTOR-ALPHA THERAPY
    • TNF-ALPHA
    • SYSTEMIC INFLAMMATION
    • PSORIATIC-ARTHRITIS

    Cite this

    @article{e3e0246836b6471db13cfc5c3527fda6,
    title = "The role of endothelial function and its assessment in rheumatoid arthritis",
    abstract = "Patients with rheumatoid arthritis (RA) have a reduced life expectancy when compared with the general population, largely attributable to cardiovascular disease. Factors that contribute to this increased cardiovascular risk include traditional risk factors, which account for only part of the excess, along with manifestations of the disease itself. RA is characterized by inflammation, which also is a key component in the development of atherosclerosis. Inflammation leads to the activation of endothelial cells, which, through an increase in the expression of leukocyte adhesion molecules, promotes a pro-atherosclerotic environment. Endothelial dysfunction is an early preclinical marker of atherosclerosis, and is commonly found in patients with RA. Several methods are available for the assessment of endothelial function, such as flow-mediated dilatation and laser Doppler flowmetry combined with iontophoresis, each with its own advantages and limitations. Studies have shown that endothelial dysfunction in RA is closely associated with inflammation, and therapeutic reduction of inflammation leads to improvements in endothelial function. As such, assessments of endothelial function could prove to be useful tools in the identification and monitoring of cardiovascular risk in patients with RA. Given the increase in cardiovascular mortality associated with RA, effective management must involve prevention of cardiovascular risk, in addition to control of disease activity and inflammation.",
    keywords = "C-REACTIVE PROTEIN, CARDIOVASCULAR RISK-FACTORS, IMPAIRED MICROVASCULAR FUNCTION, FLOW-MEDIATED DILATATION, POPULATION-BASED COHORT, CORONARY-HEART-DISEASE, FACTOR-ALPHA THERAPY, TNF-ALPHA, SYSTEMIC INFLAMMATION, PSORIATIC-ARTHRITIS",
    author = "Faisel Khan and Bernat Galarraga and Belch, {Jill J. F.}",
    year = "2010",
    month = "5",
    doi = "10.1038/nrrheum.2010.44",
    language = "English",
    volume = "6",
    pages = "253--261",
    journal = "Nature Reviews Rheumatology",
    issn = "1759-4790",
    publisher = "Nature Publishing Group",
    number = "5",

    }

    The role of endothelial function and its assessment in rheumatoid arthritis. / Khan, Faisel; Galarraga, Bernat; Belch, Jill J. F.

    In: Nature Reviews Rheumatology, Vol. 6, No. 5, 05.2010, p. 253-261.

    Research output: Contribution to journalReview article

    TY - JOUR

    T1 - The role of endothelial function and its assessment in rheumatoid arthritis

    AU - Khan, Faisel

    AU - Galarraga, Bernat

    AU - Belch, Jill J. F.

    PY - 2010/5

    Y1 - 2010/5

    N2 - Patients with rheumatoid arthritis (RA) have a reduced life expectancy when compared with the general population, largely attributable to cardiovascular disease. Factors that contribute to this increased cardiovascular risk include traditional risk factors, which account for only part of the excess, along with manifestations of the disease itself. RA is characterized by inflammation, which also is a key component in the development of atherosclerosis. Inflammation leads to the activation of endothelial cells, which, through an increase in the expression of leukocyte adhesion molecules, promotes a pro-atherosclerotic environment. Endothelial dysfunction is an early preclinical marker of atherosclerosis, and is commonly found in patients with RA. Several methods are available for the assessment of endothelial function, such as flow-mediated dilatation and laser Doppler flowmetry combined with iontophoresis, each with its own advantages and limitations. Studies have shown that endothelial dysfunction in RA is closely associated with inflammation, and therapeutic reduction of inflammation leads to improvements in endothelial function. As such, assessments of endothelial function could prove to be useful tools in the identification and monitoring of cardiovascular risk in patients with RA. Given the increase in cardiovascular mortality associated with RA, effective management must involve prevention of cardiovascular risk, in addition to control of disease activity and inflammation.

    AB - Patients with rheumatoid arthritis (RA) have a reduced life expectancy when compared with the general population, largely attributable to cardiovascular disease. Factors that contribute to this increased cardiovascular risk include traditional risk factors, which account for only part of the excess, along with manifestations of the disease itself. RA is characterized by inflammation, which also is a key component in the development of atherosclerosis. Inflammation leads to the activation of endothelial cells, which, through an increase in the expression of leukocyte adhesion molecules, promotes a pro-atherosclerotic environment. Endothelial dysfunction is an early preclinical marker of atherosclerosis, and is commonly found in patients with RA. Several methods are available for the assessment of endothelial function, such as flow-mediated dilatation and laser Doppler flowmetry combined with iontophoresis, each with its own advantages and limitations. Studies have shown that endothelial dysfunction in RA is closely associated with inflammation, and therapeutic reduction of inflammation leads to improvements in endothelial function. As such, assessments of endothelial function could prove to be useful tools in the identification and monitoring of cardiovascular risk in patients with RA. Given the increase in cardiovascular mortality associated with RA, effective management must involve prevention of cardiovascular risk, in addition to control of disease activity and inflammation.

    KW - C-REACTIVE PROTEIN

    KW - CARDIOVASCULAR RISK-FACTORS

    KW - IMPAIRED MICROVASCULAR FUNCTION

    KW - FLOW-MEDIATED DILATATION

    KW - POPULATION-BASED COHORT

    KW - CORONARY-HEART-DISEASE

    KW - FACTOR-ALPHA THERAPY

    KW - TNF-ALPHA

    KW - SYSTEMIC INFLAMMATION

    KW - PSORIATIC-ARTHRITIS

    U2 - 10.1038/nrrheum.2010.44

    DO - 10.1038/nrrheum.2010.44

    M3 - Review article

    C2 - 20351705

    VL - 6

    SP - 253

    EP - 261

    JO - Nature Reviews Rheumatology

    JF - Nature Reviews Rheumatology

    SN - 1759-4790

    IS - 5

    ER -